The Lancet Gastroenterology & Hepatology in conversation with
Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.
The Lancet Gastroenterology & Hepatology in conversation with
Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer
Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma.
Read the full article:
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup